UNSPSC 51334304: Prothixene

This classification denotes a sedative and hypnotic with the molecular formula C18H19NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2HX2OJH78L, chemically known as n,n-dimethylthioxanthene-delta(sup 9,gamma)-propylamine but generally known as prothixene, which bears US NIH Compound Identifier 71115. European Medicines Agency schedules Prothixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10139MIG.

UNSPSC 51334304 Prothixene is a Commodity code that nominally covers a specific antipsychotic medication, but recent state and local procurement activity under this code reflects broader pharmaceutical and therapeutic products procurement, including emergency medical supplies, prescription fulfillment systems, and generic multi-source pharmaceuticals. State and local buying under the code spans county health departments, state health and human services agencies, and cooperative purchasing alliances representing multiple jurisdictions. The work solicited includes direct procurement of finished pharmaceutical products for distribution through established wholesaler networks, emergency medical countermeasures such as naloxone and drug deactivation systems for community health initiatives, and pharmacy benefit program modernization through direct-to-manufacturer contracting arrangements.

Recent activity concentrates in Florida and the Upper Midwest with national cooperative purchasing reach. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., with responses due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a preliminary information-gathering mechanism to evaluate vendor capacity for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization arrangements. Vendors responding to these solicitations must maintain cGMP and Drug Supply Chain Security Act compliance, establish relationships with authorized wholesalers or direct pharmaceutical distributors, carry commercial general liability and professional liability insurance, and meet FDA requirements and shelf-life standards.